Treatment with calcifediol shortly after hospitalization with COVID-19 results in a significant reduction in intensive care unit (ICU) admission and death by more than 50 percent, reveals a study. In addition, baseline 25(OH)D levels is negatively associated with both ICU admission and mortality.
Smartwatches, with the support of machine learning algorithms, can perceive face-touching (FT) behaviours and may help contain outbreaks of respiratory infections such as the coronavirus disease 2019 (COVID-19), according to a new study.
A large retrospective study from the US, presented at IDWeek 2021, has shown that the Abbott ID NOW rapid molecular COVID-19 assay is highly sensitive and specific at detecting SARS-CoV-2 infection in a paediatric population.
Intramuscular administration of single-dose AZD7442, a combination of two long-acting monoclonal antibodies (tixagevimab and cilgavimab), significantly reduced the risk of developing symptomatic COVID-19 in adults, according to the PROVENT* study presented at IDWeek 2021.
In hospitalized COVID-19 patients, treatment with the novel GM-CSF* neutralizing monoclonal antibody lenzilumab led to a significant improvement in survival without invasive mechanical ventilation (SWOV), findings from the phase III LIVE-AIR study suggest.
A single dose of nirsevimab significantly reduced the incidence of medically attended respiratory syncytial virus (RSV)-confirmed lower respiratory tract infections (LRTIs) in healthy infants during their first RSV season, according to the MELODY* study presented at IDWeek 2021.
Older age and elevated levels of the inflammatory marker C-reactive protein (CRP) may predict mortality in COVID-19 patients, particularly if coupled with diabetes, the retrospective ACCREDIT study has shown.
The Spike single-nucleotide polymorphism (SNP) assay, a single-reaction multiplex real-time RT-PCR, provides fast, inexpensive, and sensitive detection of specific mutations associated with SARS-CoV-2 variants of concern (VoC), according to data presented at ID Week 2021.